CORT
CORCEPT THERAPEUTICS INC
NASDAQ · Healthcare · Biotechnology · US
$79.22
−3.31%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 963.6M | 761.4M | 675.0M | 482.4M | 401.9M |
| Cost of Revenue | 14.1M | 13.0M | 10.9M | 6.5M | 5.4M |
| Gross Profit | 949.5M | 748.4M | 664.2M | 475.9M | 396.5M |
| Operating Expenses | |||||
| R&D Expense | 241.7M | 254.9M | 246.9M | 184.4M | 131.0M |
| SG&A Expense | 596.9M | 448.7M | 280.3M | 184.3M | 152.8M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.00 | — | — | — | — |
| Total Operating Expenses | 838.6M | 703.6M | 527.2M | 368.6M | 283.8M |
| Cost and Expenses | 852.7M | 716.6M | 538.1M | 375.1M | 289.2M |
| Operating Income (EBIT) | 110.9M | 44.8M | 137.0M | 107.3M | 112.6M |
| Non-Operating | |||||
| Interest Income | 10.3M | 21.7M | 24.5M | 17.3M | 3.6M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 10.3M | 21.7M | 24.5M | 17.3M | 3.6M |
| Other Non-Op Income/Expense | 20.5M | 21.7M | 24.5M | 17.3M | 3.6M |
| Non-Operating Income (excl Interest) | (14.9M) | (21.7M) | (24.5M) | (17.3M) | (3.6M) |
| EBT (Pre-Tax Income) | 131.4M | 66.5M | 161.5M | 124.6M | 116.2M |
| Income Tax Expense | (35.0M) | (33.2M) | 20.3M | 18.4M | 14.8M |
| Bottom Line | |||||
| Net Income | 159.7M | 99.7M | 139.7M | 106.1M | 101.4M |
| Earnings from Cont. Ops | 166.4M | 99.7M | 141.2M | 106.1M | 101.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 159.3M | 98.2M | 139.7M | 105.5M | 101.3M |
| Per Share | |||||
| Basic EPS | $1.50 | $0.95 | $1.35 | $1.02 | $0.95 |
| Diluted EPS | $1.27 | $0.82 | $1.23 | $0.94 | $0.87 |
| Revenue Per Share | $9.04 | $7.33 | $6.54 | $4.66 | $3.76 |
| Shares | |||||
| Basic Shares Outstanding | 106.6M | 103.9M | 103.2M | 103.6M | 106.8M |
| Diluted Shares Outstanding | 123.2M | 120.0M | 113.5M | 111.7M | 116.0M |
| Profitability Metrics | |||||
| EBITDA | 127.8M | 68.4M | 162.8M | 126.9M | 119.6M |
| D&A | 1.9M | 1.9M | 1.3M | 2.4M | 3.4M |
| EBIT | 11.1M | 66.5M | 161.5M | 124.6M | 116.2M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026